ATOS (Atossa Therapeutics) GF Value Rank: 2 (As of Jul. 01, 2026) — Near Median


ATOS Atossa Therapeutics Inc ATOS
30 GF Score
Price $1.93
! 2 Warning Signs
View Full Analysis

What is Atossa Therapeutics GF Value Rank?

Atossa Therapeutics ATOS -2.03% 30 GF Value Rank is 2 as of Jul. 01, 2026, which is at its 10-year median of 2.00. GuruFocus rates ATOS with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Atossa Therapeutics has the GF Value Rank of 2.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Atossa Therapeutics GF Value Rank Related Terms


ATOS vs QNCX, ZIVO, KTTA: GF Value Rank Comparison

For the Biotechnology subindustry, Atossa Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atossa Therapeutics GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's GF Value Rank falls into.


ATOS
30GF Score
Atossa Therapeutics Inc ATOS
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 2 mean?
Atossa Therapeutics (ATOS) has a GF Value Rank of 2 as of Jul. 01, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Atossa Therapeutics and its competitors. This is near median its historical median of 2.00. Over the past decade, Atossa Therapeutics' GF Value Rank has ranged from 1.00 to 6.00.
Is Atossa Therapeutics' GF Value Rank too high?
Atossa Therapeutics' current GF Value Rank of 2 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. Overall, Atossa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' GF Value Rank compare to QNCX and ZIVO?
Atossa Therapeutics' GF Value Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Atossa Therapeutics' own GF Value Rank has ranged from 1.00 to 6.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Atossa Therapeutics and its competitors. Atossa Therapeutics's current GF Value Rank is 2, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (ATOS) has a current GF Value Rank of 2. The current GF Value Rank is 2, which is near median its 10-year median of 2.00. Atossa Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Atossa Therapeutics (ATOS), the current GF Value Rank is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atossa Therapeutics Business Description

Other Exchanges ATOS:MexicoYAG:Germany
Address 1448 NW Market Street, Suite 500, Seattle, WA, USA, 98107
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
30GF Score

Get the complete analysis for ATOS

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93
Price